Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB EBITDA Margin
EBITDA as a percentage of revenue.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025
EBITDA Margin not reported for Q4 FY2025
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -721.5% for the fiscal year ending Dec 2026, up from -85279.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- —— QoQ
- Last fiscal yearDec 2025
- -85279.7%-85223.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -85223.0 pp | +84558.2 pp | +169781.2 pp |
| 3 years | — | +84673.9 pp | — |
| 5 years | +85240.3 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -85279.7%
- Year-over-year change
- -85223.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -85279.7% | -85223.0pp |
| FY2024 | 2024-12-31 | -56.6% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How CNTB compares with its peers on the latest reported figures
- CNTB's FY2025 EBITDA Margin of -85279.7% is the 5th highest of the 6 companies compared; the peer median is -4623.1%.
- Its year-over-year change of -85223.0 pp is the 5th highest of 6, against a peer median of -3172.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -106.5% | +169.1 pp | +12.9 pp | |
| LTM Mar 2026 | -337.0% | +4411.9 pp | +3368.5 pp | |
| LTM Mar 2026 | -4623.1% | -3172.4 pp | +10652.3 pp | |
IMAImageneBio Inc | FY2025 | -5583.3% | -4582.4 pp | -5147.8 pp |
| FY2025 | -85279.7% | -85223.0 pp | — | |
| LTM Mar 2026 | -144435.8% | -111246.8 pp | — | |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
KLRSKalaris Therapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding CNTB) | -4623.1% | -3172.4 pp | +1690.7 pp | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.